Latest News and Press Releases

Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI® with one-third of patients with relapsed/refractory multiple myeloma progression-free for...

An oral presentation at ASCO & EHA Congress from the CARTITUDE-1 study highlighting heavily pre-treated patients that remain alive and progression-free for more than 5 years after a single...

SOMERSET, N.J., May 19, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday,...

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $369 millionOver 6,000 patients treated to dateInitiated CARVYKTI® clinical production at the Tech Lane...

SOMERSET, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am...

CARVYKTI® net trade sales of approximately $334 million and $963 million for the fourth quarter and full year 2024, respectivelyOver 5,000 patients treated to dateInitiated commercial production of...

SOMERSET, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET...

SOMERSET, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s...

89 percent of evaluable patients achieved minimal residual disease (MRD) negativity with CARVYKTI® after three-year follow-up in CARTITUDE-4 study; the majority in less than 2 monthsResults add to the...

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) updates: Net trade sales of approximately $286 million, representing operational growth of 87.6% year-over-year and 53.2% quarter-over-quarterFirst...